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FOOD ADDITIVES AS INHIBITORS OF INTESTINAL DRUG TRANSPORTER OATP2B1 
 







Food additives are compounds that are added to food and beverage to improve taste, color, preservation or 
composition. Generally, food additives are considered safe for human use due to safety evaluation conducted by 
food safety authorities and high safety margins applied to permitted usage levels. However, the interaction 
potential of food additives with simultaneously administered medication has not received much attention. Even 
though many food additives are poorly absorbed into systemic circulation, high concentrations could exist in the 
intestinal lumen making intestinal drug transporters, such as the uptake transporter organic anion transporting 
polypeptide 2B1 (OATP2B1), a possible site of food additive–drug interaction. In the present work, we aimed to 
characterize the interaction of a selection of 25 food additives including colorants, preservatives and sweeteners 
with OATP2B1 in vitro. In HEK293 cells transiently overexpressing OATP2B1 or control, uptake of 
dibromofluorescein was studied with and without 50 µM food additive at pH 7.4. As OATP2B1 displays substrate- 
and pH-dependent transport function and the intraluminal pH varies along the gastrointestinal tract, we performed 
the studies also at pH 5.5 using estrone sulfate as OATP2B1 substrate. Food additives that inhibited OATP2B1-
mediated substrate transport with ≥50% were subjected to dose-response studies. Six colorants were identified and 
validated as OATP2B1 inhibitors at pH 5.5, but only three of these were categorized as inhibitors at pH 7.4. One 
sweetener was validated as an inhibitor at both assay conditions whereas none of the preservatives exhibited ≥50% 
inhibition of OATP2B1-mediated transport. Extrapolation of computed inhibitory constants (Ki values) to 
estimations of intestinal food additive concentrations imply that selected colorants could inhibit intestinal 
OATP2B1 also in vivo. These results suggest that food additives, especially colorants, could alter the 
pharmacokinetics of orally administered OATP2B1 substrate drugs, although further in vivo studies are warranted 










ABC-transporter, ATP-binding cassette transporter 
ADI, acceptable daily intake 
BCRP, breast cancer resistance protein (ABCG2) 
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Food additives are substances widely added to processed food to improve their taste, color, preservation or 
composition. In the European Union, the use of food additives is controlled by legislation (Regulation (EC) No 
1333/2008 of the European Parliament and Council). The European Food Safety Authority (EFSA) evaluates the 
safety and establishes acceptable daily intake (ADI), defined as the safe amount of food additive to be consumed 
daily, for each food additive. The evaluation of food additive safety by authorities as well as scientific research 
has mainly focused on toxicity issues such as acute and chronic toxicity, carcinogenicity, genotoxicity, 
developmental and reproductive toxicity and hypersensitivity.1 However, the interaction potential of food additives 
with concurrently administered medication has not received much attention. Interindividual variability in drug 
pharmacokinetics is a major concern affecting especially drugs with narrow therapeutic range, and food–drug 
interactions are known to be a source of variability in many circumstances.2 Even though many food additives are 
poorly absorbed and hardly reach the systemic circulation,1 they could affect drug pharmacokinetics by altering 
the function of drug transporters they encounter during gastrointestinal (GI) transit. 
 
It is increasingly acknowledged that pharmaceutical excipients used for drug formulation, some of which are also 
used as food additives, are not pharmacokinetically inert as they can interact with GI phase I and phase II 
metabolizing enzymes as well as drug transporters.3,4 For example, in different cell and animal models, the major 
intestinal ATP-binding cassette (ABC) drug transporters, P-glycoprotein (P-gp), breast cancer resistance protein 
(BCRP) and multidrug resistance associated protein 2 (MRP2), are inhibited by excipients such as the surfactants 
Cremophor EL, Tween 20 or Tween 80.3 Previously in our group, we identified several colorants capable of 
inhibiting BCRP and MRP2 in vitro with low micromolar IC50 values.
5 Also others have reported similar results 
for the inhibition of BCRP.6 Even though drug formulations infrequently contain high amounts of these additives, 
higher concentrations may be present in food products. For example, in extreme cases, the intestinal concentrations 
after dietary exposure of selected azo dyes could exceed BCRP and MRP2 IC50 values more than 100-fold, 
suggesting that also in vivo inhibition of these transporters could occur.5 In addition to intestinal efflux transporters, 
cellular uptake transporters localized on the membrane facing the intestinal lumen could be exposed to high food 
additive concentrations and, thus, be a site of food additive–drug interaction. However, knowledge about the 
impact of drug or food additives on the function of uptake transporters is limited.3,4 In a few studies, pharmaceutical 
excipients, such as solubilizing agents hydroxypropyl-β-cyclodextrin, Solutol HS 15 and Cremophor EL, have 
been shown to inhibit the main intestinal organic anion transporting polypeptide (OATP), OATP2B1, and other 
intestinal drug uptake transporters.7,8 
 
OATP2B1, encoded by the SLCO2B1 gene, is expressed widely in many tissues including liver hepatocytes and 
importantly, along the entire intestine.9,10 However, there are contradicting findings regarding the apical or 
basolateral localization of the transporter in enterocytes.11,12 OATP2B1 accepts a wide range of drugs as its 
substrate in vitro, such as the antihistamine fexofenadine, lipid-lowering agents fluvastatin and rosuvastatin, and 
anti-inflammatory drug sulfasalazine.10 Even though the evaluation of the role of OATP2B1 in drug 
pharmacokinetics has quickly evolved in recent years, this research is relatively new compared to other drug 
transporters, and currently the evidence of OATP2B1 contribution to drug–drug interactions is limited.13 However, 
intestinal OATP2B1 is recognized as a mediator of several clinical food–drug interactions, where inhibition of 
OATP2B1 by common fruit juices has decreased the oral bioavailability of OATP2B1 substrates, such as aliskiren, 
celiprolol and fexofenadine, with more than 60%.14–16 The involvement of OATP2B1 on drug absorption is 
supported by studies where the genetic variant SLCO2B1-c.1457C>T (rs2306168) has been associated to 
decreased intestinal absorption of fexofenadine and celiprolol.14,15 In addition, recent knockout studies in mice 
suggest that the mouse orthologue for OATP2B1, Oatp2b1, is involved in the oral absorption of OATP2B1 
substrates fexofenadine and fluvastatin.17,18 With this background, the International Transporter Consortium (ITC) 
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introduced OATP2B1 as a clinically emerging transporter for drug development and recommended at least 
retrospective evaluation of OATP2B1 contribution to drug pharmacokinetics.19  
 
Considering the emerging clinical significance of OATP2B1 and the gap in knowledge on food additive–drug 
interactions, the aim of this study was to characterize the potential of a set of food additives to inhibit OATP2B1 
in vitro. The selected 25 food additives included 9 colorants, 6 preservatives and 10 sweeteners commonly used 
in Europe, and have been previously examined for intestinal efflux transporter inhibition.5 As OATP2B1 displays 
substrate- and pH-dependent transport function,12,20,21 we performed studies at pH 5.5 in addition to standard assay 
conditions at pH 7.4 and used the endogenous OATP2B1 substrate estrone sulfate and fluorescent substrate 
dibromofluorescein (DBF), respectively, as OATP2B1 probes. Finally, comparison of calculated inhibitory 
constants with estimations of intestinal food additive concentrations reveal that in vivo inhibition of intestinal 




MATERIALS AND METHODS 
 
Materials 
Food additives and other chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise 
stated. All food additives had ≥96% purity except betanin, curcumin (≥65 %) and Sunset Yellow FCF (dye content 
90%). The food additives were dissolved in DMSO at 4–20 mM. Dulbeccos’s modified eagle medium (DMEM; 
high glucose, GlutaMAX Supplement), Hank’s balanced salt solution (HBSS) and fetal bovine serum (FBS) were 
obtained from Thermo Fisher Scientific (Waltham, MA, USA). [3H]-Estrone sulfate ammonium salt (specific 
activity range 40–60 Ci/mmol) and Optiphase Hisafe 3 scintillation liquid were from PerkinElmer (Boston, MA, 
USA).  
 
Preparation of SLCO2B1 carrying vectors  
The full length protein coding sequence of SLCO2B1 (NCBI Reference Sequence: NM_007256.5) was cloned 
with polymerase chain reaction (PCR) from human adult normal liver tissue  (BioChain, San Francisco, CA, USA). 
The primers were 5’-TGCAGTCGACCAGTCATGGGACCCAG-3’ and 5’-
GAGGATTCCCGAGTGTGAGAATTCTTGGG-3’ and were designed to contain SalI and EcoRI restriction sites, 
which were used to clone the insert into Gateway pENTR4 dual selection vector with T4 DNA Ligase (Thermo 
Fisher Scientific). For eukaryotic translation initiation, a kozak consensus sequence (GCC GCC ACC) was added 
in front of the translation initiation codon with site-directed mutagenesis (Q5 Site-Directed Mutagenesis Kit, New 
England Biolabs, Ipswich, MA, USA). Eurofins Genomics sequencing service (Edersberg, Germany) was used to 
verify the correct sequence of SLCO2B1.  
 
Preparation of recombinant SLCO2B1 carrying baculoviruses for transient expression of OATP2B1 in HEK293 
cells was conducted according to manufacturer’s protocols (Bac-to-Bac Baculovirus Expression System and 
ViraPower BacMam Expression System from Thermo Fisher Scientific) and as previously described for ABCG2.22 
In brief, from the pENTR4 entry vector, the SLCO2B1 gene was transferred into a modified Bac-to-Bac destination 
vector with Gateway LR Clonase II enzyme mix (Thermo Fisher Scientific). Purified plasmid construct was 
transformed into competent DH10Bac E. Coli cells for transposition into bacmid. Cellfectin II reagent (Thermo 
Fisher Scientific) was used to transfect adherent Sf9 cells with recombinant bacmid DNA. The cells were incubated 
for seven days at 27 °C before harvesting recombinant baculovirus. This P1 viral stock was further amplified to 
yield P2 and P3 baculovirus stocks by infecting Sf9 cells with the harvested baculovirus and incubating for seven 
days at 27 °C. Baculovirus containing the gene for enhanced yellow fluorescence protein (eYFP) were produced 
similarly to be used as negative control in the HEK293 uptake assay. 
 
HEK293 uptake assay  
HEK293 cells were routinely cultured in DMEM supplemented with 10% FBS at 37 °C and 5% CO2. For the 
uptake assay, HEK293 cells were seeded at 50 000 cells/well on Nunclon Delta Surface 48-well plates (Thermo 
Fisher Scientific) coated with poly-D-lysine, or CellBind 48-well plates (Corning, NY, USA) and incubated 
overnight at 37 °C and 5% CO2. The growth medium was replaced with transduction mix with 5 mM sodium 
butyrate and recombinant SLCO2B1 or eYFP (control) P3 baculovirus in DMEM supplemented with 10% FBS.  
 
The uptake assay was initiated approximately 48 hours later by pre-incubating cells with transport buffer with pH 
7.4 or pH 5.5 for 5 minutes at 37 °C. The transport buffer was composed of 25 mM HEPES (pH 7.4) or MES (pH 
5.5) and 4.17 mM NaHCO3 in HBSS adjusted to the assigned pH with NaOH. After the pre-incubation, transport 
buffer was replaced with test solution containing OATP2B1 probe substrate in transport buffer, and incubated at 
37 °C while keeping the assay plate well-stirred in an orbital shaker. The uptake was terminated by washing cells 
three times with ice-cold transport buffer. Probe substrates used were 4 ,́ 5´-dibromofluorescein (DBF) at pH 7.4, 
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and estrone sulfate at pH 5.5. A range of substrate concentrations and incubation times were tested to find the 
linear part of substrate transport.  
 
The set of food additives was tested for OATP2B1 inhibition at 50 µM concentration. DMSO concentration of test 
solution was kept below 1.5%. Concentrations and incubation times of OATP2B1 substrates were chosen from 
the linear transport zone and were 1 µM (5 minutes) and 0.5 µM (2–3 minutes) for DBF and estrone sulfate, 
respectively. Food additives that inhibited OATP2B1-mediated transport of substrate with ≥50% were selected for 
dose–response studies for half-maximal inhibitory concentration (IC50) determination.  
 
Sample analysis 
DBF samples. Cells were lysed with 0.1 M NaOH for 10 minutes before measuring cellular drug accumulation. 
DBF lysates were analyzed with fluorescence detection using Varioskan LUX microplate reader (Thermo Fisher 
Scientific) with 503 nm excitation and 525 nm emission.  
 
Estrone sulfate samples. Inhibition and optimization studies with estrone sulfate were performed with radiolabeled 
substrate whereas LC-MS/MS detection was used to determine transport kinetics of estrone sulfate due to high 
consumption of substrate. [3H]-Estrone sulfate containing cells were lysed in 0.1 M NaOH and subsequently 
neutralized with equivalent moles of 1 M HCl before adding Optiphase HiSafe 3 scintillation liquid and measuring 
radioactivity of samples with MicroBeta2 2450 Microplate Counter (PerkinElmer). Estrone sulfate from transport 
kinetics samples were quantitated with ultra-high pressure liquid chromatography tandem mass spectrometry 
instrument (UPLC-MS/MS) (Waters, MA, USA). Cells were lysed with 3:1 methanol-water solution containing 
25 ng/mL estrone sulfate D5 as internal standard (ISTD). After incubation for 30 minutes, the lysates were 
centrifuged at 14 000g for 10 minutes. Analytes in the supernatant were separated on a liquid chromatography 
coupled with Waters UPLC HSS T3 column (1.8 μm, 2.1 × 100 mm) at 40 °C, while injection volume was 1 µL. 
Mobile phase consisted of 0.1% of formic acid (Merck, Darmstadt, Germany) in ultrapure water (A) and 100% of 
LC-MS grade acetonitrile (Honeywell, Seelze, Germany) (B). Gradient elution started with 20% of B at 0–0.5 
minutes, continued with 20–95% B at 0.5–2 minutes, while complete run time was 5 minutes including column 
wash and equilibration. The flow rate was set to 0.4 mL/min. 
 
Mass spectrometric measurements were carried out using Waters Xevo TQ-S triple quadrupole mass spectrometer 
coupled with an electrospray ionization (ESI) on a negative mode. Optimized ms-parameters were as follows: 
capillary 1.5 kV, cone voltage 80 V for estrone sulfate and 86 V for ISTD, source temperature 150 °C and 
desolvation temperature 600 °C. Nitrogen (AGA, Helsinki, Finland) was used as desolvation gas (600 L h−1) and 
cone gas (150 L h−1), and argon (AGA) as collision gas. The multiple reaction monitoring mode was employed for 
quantification. Precursor and fragment ions were for estrone sulfate 349.02 > 269.35 (collision energy (CE) 31 V) 
and for ISTD 354.05 > 274.36 (CE 32 V). Resulting data was analyzed with Waters MassLynx V4.1 software. 
 
Data analysis 
OATP2B1-mediated uptake of substrates was calculated by subtracting background passive uptake obtained from 
eYFP transduced control wells and normalizing to test solution incubation time and average total protein amount 
in wells (typically 0.02–0.10 mg/well) measured with Pierce Coomassie (Bradford) Assay kit (ThermoFisher 
Scientific). The percentage of OATP2B1-mediated uptake inhibited by the food additives was obtained by 
normalizing the uptake of substrate to control, where cells were incubated with substrate only.  
 
The IC50 values were calculated with GraphPad Prism version 6.07 (GraphPad Software, San Diego, CA, USA) 




Substrate uptake (% of control) = Bottom +
Top − Bottom








According to the model, bottom and top values are the maximum and minimum plateaus of the curve. The bottom 
plateau was constrained to zero, and, if necessary, top value to 100. [I] is the inhibitor concentration, and the Hill 
Slope describes the steepness of the curve. Inhibition constant (Ki) values were extrapolated from the IC50 values 
according to the Cheng-Prusoff equation (eq. 2) assuming that inhibition mode is competitive and only one 
substrate/inhibitor binding site is involved.23,24 However, it should be noted that multiple binding sites on 










In eq. 2, [S] is the substrate concentration and Km is the Michaelis-Menten constant. The Km values for OATP2B1-
mediated transport of DBF at pH 7.4 and estrone sulfate at pH 5.5 were defined with the HEK293 uptake assay by 
measuring substrate uptake in OATP2B1 and control transduced cells with different substrate concentrations and 
fitting the data with non-linear regression with Graphpad Prism.  
 
Molecular properties of compounds were calculated with ACD/Labs version 8.0 (Advanced Chemistry 
Development, Inc., Toronto, ON, Canada). 
 
Assay interference studies 
Assay interference studies were performed as previously described5 to exclude false positive or negative results 
due to aggregation of food additives, intrinsic fluorescence of food additives or quenching of DBF fluorescence 
signal. Aggregation of 50 µM food additives in the transport buffer at pH 7.4 and pH 5.5 was tested using 
Nepheloskan Ascent nephelometer (Thermo Fisher Scientific). When aggregation was observed, further dilutions 
of the food additives were made to find solubility limits. Quenching of DBF fluorescence or intrinsic fluorescence 
of food additives were assayed by mimicking the assay conditions by measuring the fluorescence of 0.1 µM DBF 
with 50 µM food additive in 0.1 M NaOH. These conditions assume that all of the food additive in the inhibition 
assay would be taken up by the cells and retained in the final sample elute, which is not likely. If fluorescence 
interference was observed in these conditions, DBF fluorescence was measured together with lower concentrations 
of food additives assuming that 20% (10 µM), 10% (5 µM) or 2% (1 µM) of the initial 50 µM food additive would 
be retained in the final fluorescence sample.  
 
Statistical analysis 
The single concentration (50 µM) food additive testing was performed once with three replicate wells. The IC50 
assays were repeated on 3–4 independent occasions with three replicates each (n = 3–4). Kinetic assays were 
performed once with three replicate wells.  
Statistical significance was calculated with unpaired student’s t-test or when multiple groups were compared, one-







The uptake of DBF into OATP2B1 and control (eYFP) transduced HEK293 cells was studied at pH 7.4. 
OATP2B1-mediated uptake of DBF was time- (Supporting Information Figure S1) and concentration-dependent 
with a Km value of 2.7 ± 0.29 µM (Figure 1A). High passive background uptake of DBF (apparent pKa 6.69 [most 
acidic]; logD5.5 4.87) in control transduced cells at pH 5.5 impeded the use DBF as OATP2B1 substrate at this pH 
(data not shown). Estrone sulfate (pKa not applicable; logD5.5 0.01) demonstrated time- (Supporting Information 
Figure S1) and concentration-dependent OATP2B1-mediated uptake with low background uptake and a Km value 
of 12.9 ± 3.2 µM at pH 5.5 (Figure 1B). The transport affinity of both substrates was comparable with previously 
published data.26–28 
 
Figure 1. Concentration-dependent uptake of (A) dibromofluorescein (DBF) and (B) estrone sulfate into HEK293 
cells expressing OATP2B1 (○) or control (□). OATP2B1-mediated uptake (●) was obtained by subtracting control 
uptake from OATP2B1 uptake. Uptake of DBF was studied at pH 7.4 over 5 minutes and uptake of estrone sulfate 
at pH 5.5 over 2 minutes. The data is presented as mean ± SD from one study with three replicate wells. Data used 
to create the figures is presented in Supporting Information Table S1 and S2.  
 
 
The potential to inhibit OATP2B1-mediated uptake of DBF at pH 7.4 and estrone sulfate at pH 5.5 was tested for 
a set of 25 food additives at 50 µM concentration (Figure 2 and Supporting Information Table S4). Three of the 
colorants (Allura Red AC, Carmoisine and curcumin) inhibited OATP2B1-mediated transport of DBF and estrone 
sulfate with ≥50%. Three additional colorants (Brilliant Black BN, Brilliant Blue FCF and Sunset Yellow FCF) 
were characterized as inhibitors only when estrone sulfate was used as substrate. None of the preservatives 
inhibited OATP2B1-mediated transport with over 50% compared to the control. Neohesperidin dihydrochalcone 
(DC) was the only sweetener identified as an OATP2B1 inhibitor at both assay conditions while rebaudioside A 
inhibited OATP2B1-mediated DBF uptake ≥50%. Sucralose seemed to increase OATP2B1 mediated uptake of 





Figure 2. Inhibition of OATP2B1-mediated uptake of 1 µM dibromofluorescein (DBF) at pH 7.4 (black bars) or 
0.5 µM estrone sulfate (ES) at pH 5.5 (gray bars) by a selection of 25 food additives including colorants, 
preservatives and sweeteners. OATP2B1 and control overexpressing HEK293 cells were incubated with 50 µM 
food additive and substrate to define percent of OATP2B1 uptake inhibited. Food additives that inhibited 
OATP2B1-mediated uptake more than 50% (dashed line) were selected for dose-response studies. The results are 





Based on the initial single inhibitor concentration assay, potential OATP2B1 inhibitors were selected for dose-
response studies to determine IC50 (Figure 3 and Table 1), which were then used to extrapolate Ki values according 
to the Cheng-Prusoff equation. Because substrate concentrations used were well below Km values, the calculated 
Ki values were close to the IC50 values determined experimentally. Allura Red AC was identified as the strongest 
inhibitor at both conditions with Ki values 0.6 ± 0.3 µM and 1.5 ± 0.5 µM at pH 7.4 and pH 5.5, respectively. 
Rebaudioside A inhibited OATP2B1-mediated uptake of DBF (pH 7.4) with ≥50% at 50 µM concentration (Figure 
2), but dose-dependent inhibition was not observed (data not shown). The Ki value of Carmoisine was significantly 
lower at pH 5.5 compared to pH 7.4 (p = 0.013), while Allura Red AC, curcumin and neohesperidin DC had 







Figure 3. Inhibitory curves of OATP2B1-mediated uptake of 1 µM dibromofluorescein (DBF) at pH 7.4 (●) and 
0.5 µM estrone sulfate at pH 5.5 (○) by selected food additives in HEK293 overexpression system. Brilliant Black 
BN, Brilliant Blue FCF and Sunset Yellow FCF were characterized as inhibitors only at pH 5.5. Data is presented 




Table 1. Half-maximal inhibitory concentrations (IC50) and extrapolated inhibition constant (Ki) values for selected 
food additives at pH 7.4 (DBF as substrate) and pH 5.5 (estrone sulfate). IC50 are expressed as mean ± SD 
calculated from values obtained from 3–4 individual experiments (n = 3–4) with three replicate wells. Ki values 
were calculated from the IC50 values with the Cheng-Prusoff equation.
23,24  
Food additive 




Allura Red AC IC50 0.8 ± 0.4 1.6 ± 0.6 
 Ki 
 
0.6 ± 0.3 1.5 ± 0.5 
Brilliant Black BN IC50 a 3.9 ± 0.4 
 Ki 
 
a 3.8 ± 0.3 
Brilliant Blue FCF IC50 a 18.4 ± 2.6 
 Ki 
 
a 17.7 ± 2.5 
Carmoisine IC50 9.7 ± 2.6 2.9 ± 0.3 
 Ki  
 
7.0 ± 1.9* 2.7 ± 0.3* 
Curcumin IC50 6.9 ± 1.0 5.4 ± 1.0 
 Ki 
 
5.0 ± 0.7 5.3 ± 1.0 
Neohesperidin DC IC50 48.6 ± 17.4 15.5 ± 1.6 
 Ki 
 
35.4 ± 12.7 14.9 ± 1.5 
Sunset Yellow FCF IC50 a 20.3 ± 1.0 
 Ki a 19.6 ± 1.0 
a IC50 is above 50 µM according to the single inhibitor concentration assay and, therefore, IC50 (and Ki) was not determined    






To evaluate whether the difference in OATP2B1 inhibitory activity at pH 7.4 and pH 5.5 observed for Brilliant 
Black BN, Brilliant Blue FCF and Sunset Yellow FCF was due to the different extracellular pH or different 
substrate used, we tested their OATP2B1 inhibition of estrone sulfate transport also at pH 7.4 at 50 µM 
concentration (Figure 4). Brilliant Black BN displayed pH-dependent activity as no inhibition was observed at pH 
7.4 regardless of the substrate. Brilliant Blue FCF demonstrated ≥50% transport inhibition only at pH 5.5, but  
decrease in transport function was observed also at pH 7.4 for both substrates. The inhibitory activity of Sunset 
Yellow FCF seemed to be mostly substrate-dependent since inhibition of estrone sulfate at pH 7.4 and pH 5.5 were 
comparable but differed from DBF uptake inhibition at pH 7.4 (p < 0.05).   
 
   
Figure 4. Substrate- and pH-dependent inhibition of OATP2B1-mediated uptake of dibromofluorescein (DBF; 1 
µM) at pH 7.4, and estrone sulfate (ES; 0.5 µM) at pH 7.4 and pH 5.5 by selected food additives. Concentration 
of food additive was 50 µM (40 µM for Brilliant Black inhibition of estrone sulfate transport). Results are 
expressed as mean ± SD from one study with three replicates except for estrone sulfate (pH 5.5), where results are 
expressed as mean ± SD from three independent studies with three replicates. Data was partly integrated from 
inhibitor identification assays (Figure 2) and dose-response studies (Figure 3). *p < 0.05 compared to ES (pH 5.5), #p 
< 0.05 compared to DBF (pH 7.4).  
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To rule out false positive or negative results due to fluorescence interference of test compounds or poor aqueous 
solubility of food additives, assay interference studies were performed. Quenching of DBF fluorescence signal 
was observed for nine compounds when DBF fluorescence was measured together with 50 µM food additive 
(Supporting Information Figure S2). Four of these compounds (Allura Red AC, Carmoisine, curcumin and 
rebaudioside A) were identified as OATP2B1 inhibitors at pH 7.4 in the initial inhibition assay. However, as it is 
very unlikely that all of the food additive is taken up into the cells during the uptake assay, the fluorescence 
interference was then tested with lower concentrations for these four compounds. When it was assumed that 10% 
(5 µM) or less of the food additive is retained in the final sample elute in the uptake assay, quenching of DBF 
fluorescence was less than 10% for all four compounds (Figure 5A). 
 
The solubility of the food additives in transport buffer was tested to rule out OATP2B1 inhibition by aggregates. 
Only curcumin displayed clear aggregation at the 50 µM test concentration at pH 7.4 and pH 5.5 and was subjected 
to further studies (Figure 5B; Supporting Information Figure S3). At both pH conditions, curcumin had a similar 
solubility profile, with significant aggregation observed at concentrations over 1 µM (p < 0.05). 
 
 
Figure 5. A) Fluorescence interference of selected food additives with 0.1 µM dibromofluorescein (DBF) assuming 
that 100% (50 µM), 20% (10 µM), 10% (5 µM) or 2% (1 µM) of the initial food additive in the HEK293 uptake 
assay would be retained in final samples. Results are expressed as relative fluorescence of 0.1 µM DBF with food 
additive compared to DBF fluorescence alone. B) Solubility of curcumin in transport buffer (pH 7.4 and pH 5.5) 
measured with nephelometry. Results are expressed as mean ± SD (three replicates) relative nephelometric unit 






In this study, we identified seven food additives as OATP2B1 inhibitors from a selection of 25 commonly used 
colorants, preservatives and sweeteners. With the exception of the sweetener neohesperidin DC, all OATP2B1 
inhibitors were color additives. Moreover, the inhibitors were mostly azo dyes as Allura Red AC, Brilliant Black 
BN, Carmoisine and Sunset Yellow FCF share the functional group diazenyl R-N=N-R’ (Supporting Information 
Figure S4). In general, high molecular weight and, conversely, both lipophilicity and polarity are characteristic for 
OATP inhibitors.29 Among the studied food additives, most OATP2B1 inhibitors were rather polar and of high 
molecular weight, as they had calculated logD7.4 and logD5.5 between -7.64 to -0.17 and molecular weights above 
350 Da (Supporting Information Table S3). The calculated logD7.4 and logD5.5 of neohesperidin DC and curcumin 
were higher, ranging from 2.59 to 3.08. Assay interference studies indicated that curcumin inhibitor properties 
could have been affected by aggregates in the test solution. However, clear curcumin dose-dependent inhibition 
of OATP2B1 was observed notwithstanding the inhibition mechanism by curcumin specifically or its aggregates. 
Our findings regarding the inhibitory potential of curcumin are also in agreement with a previous study where 10 
µM curcumin significantly inhibited OATP2B1-mediated transport of estrone sulfate at pH 7.4.30 
 
During the review process of this manuscript, a study investigating food and drug additives as OATP2B1 inhibitors 
was published.31 Similar to our study, OATP2B1 inhibitors identified in this study were mostly color additives 
and, furthermore, enriched in azo dyes. When DBF was used as substrate, comparable Ki values were obtained for 
Allura Red AC and neohesperidin DC in both studies, and the Ki value of Sunset Yellow FCF (68.4 µM) is also 
in agreement with our screening result with DBF at pH 7.4. However, we defined lower Ki values for Allura Red 
AC (1.5 µM versus 10.5 µM31) and Sunset Yellow FCF (19.6 µM versus 54.2 µM31) when estrone sulfate was 
used as substrate, which is possibly explained by our acidic assay condition compared to neutral pH used by Zou 
et al.31 We did not observe significant OATP2B1 inhibition of DBF uptake by 50 µM Brilliant Blue FCF (uptake 
84.7% of control), but Zou et al.31 reported marked decrease of DBF transport by 200 µM Brilliant Blue FCF and 
defined a Ki value of 13.0 µM, which is comparable with the Ki value we obtained for estrone sulfate at pH 5.5. 
We used only a single concentration (50 µM) in the initial inhibitor identification assay, and advanced food 
additives inhibiting OATP2B1 transport ≥50% for dose-response studies, which could have underestimated the 
prevalence of relevant inhibitors among food additives that are present in high amounts in food products. However, 
ten of the inactive food additives in our study were included in the study by Zou et al.,31 and were not identified 
as OATP2B1 inhibitors even though Zou et al. used mostly higher concentrations (200–1000 µM) for the initial 
single concentration inhibitor screen. Comparison of these results from our study and the study by Zou et al.31 are 
summarized in Supporting Information Table S4. 
 
The function of OATP2B1 is known to be largely substrate- and perpetrator-dependent, a phenomenon explained 
at least partly by multiple binding sites on OATP2B1 and best described for estrone sulfate transport.21,25 
OATP2B1 has low- and high affinity sites for estrone sulfate, which, however, are not necessarily completely 
common with binding sites for other substrates.25 Also perpetrators may alter the function of either the low- or 
high-affinity site or both, and yet the possibility of allosteric binding sites cannot be excluded.25,32,33 Furthermore, 
perpetrators can either stimulate or inhibit these binding sites independently, as progesterone stimulates the uptake 
of estrone sulfate by the high-affinity site but rather inhibits the low-affinity site.25 In addition to significant 
OATP2B1 inhibition by food additives, we observed an apparent OATP2B1 stimulating effect for sucralose, which 
increased OATP2B1 mediated uptake of DBF with ≥50% at pH 7.4 but not uptake of estrone sulfate at pH 5.5. 
These findings may be an artifact of screening with a single concentration, as Zou et al.31 did not observe any 
effect on OATP2B1-mediated transport of DBF with 1000 µM sucralose. However, due to the complicated nature 
of OATP2B1 modulation described above, the stimulation of OATP2B1 by sucralose could be substrate- and also 
concentration-dependent similar to progesterone, which stimulates OATP2B1 at lower concentrations but the 
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stimulatory effect fades out with higher concentrations.32 The apparent stimulatory effect of food additives require 
further experiments dedicated for this purpose, as well as studies addressing the overall clinical relevance of 
OATP2B1 stimulation, which is currently lacking.33,34  
 
OATP2B1 has maximal functional activity at an acidic extracellular environment,20,26 which can be relevant in the 
intestine, where orally administered drugs are exposed to a pH gradient. Therefore, the International Transporter 
Consortium has suggested that incorporation of acidic assay conditions to standard OATP2B1 in vitro studies at 
neutral pH could improve translation of in vitro results to the clinical situation.19 The luminal pH can vary from 
about 4.5 to 8.0 in different intestinal segments, but the pH-microclimate at the epithelial cell surface is typically 
between 5.2 and 6.7.35,36 Considering the pH- and substrate-dependent function of OATP2B1, we included studies 
with estrone sulfate at pH 5.5 to accompany findings from neutral assay conditions with DBF, and identified three 
colorants that inhibited OATP2B1 at pH 5.5 but not at pH 7.4. However, as these observations could be due to 
change in extracellular pH and/or different substrates between the two conditions, we then tested the inhibition of 
estrone sulfate also at pH 7.4 for the three additives that were identified as inhibitors of estrone sulfate transport 
at pH 5.5 but not DBF at pH 7.4 (Figure 4). An apparent pH-dependent inhibitory effect of Brilliant Black BN was 
observed as no inhibition was evident at pH 7.4 regardless of the substrate, but the inhibitor activity of Brilliant 
Blue FCF and Sunset Yellow FC was more diverse. These findings could be explained by the multiple binding 
sites on OATP2B1 as only the low affinity estrone sulfate binding site shows pH-dependent substrate transport.21 
The effect of extracellular pH on OATP2B1 inhibitor activity has not been comprehensively studied. Varma et 
al.20 studied the inhibitor properties of rifamycin SV on OATP2B1-mediated uptake of estrone sulfate and 
rosuvastatin and observed similar profiles at pH 7.4 and pH 6.0. Our results suggest that OATP2B1-inhibition is 
pH-, substrate- and perpetrator-dependent, which complicates the extrapolation of results from one substrate and 
perpetrator to another and that care should be taken also to choose in vitro assay conditions carefully to imitate the 
in vivo site of inhibition. 
 
Although systemic absorption of especially many colorants is negligible,1 concentrations in the intraluminal space 
of the GI tract can be high due to high amounts of additives in food and beverage. For example, detected 
concentrations of Allura Red AC in drinks and juices can vary from 0.1 to over 2000 mg/kg.5 According to 
European Medicines Agency (EMA) guidance on drug interactions, in vivo inhibition of intestinal transporters 
cannot be ruled out if observed Ki values are lower than maximum expected concentration in the intestinal lumen, 
which is defined as 0.1-fold the maximum dose on one occasion/250 ml.37 However, the maximum single doses 
of food additives are difficult to estimate, because additive amounts in food can vary from product to product, 
consumption patterns are individual, and the daily additive intake is not typically ingested as a single bolus. To 
evaluate the possibility of in vivo inhibition of OATP2B1 by selected food additives, we decided to use EFSA 
estimates of maximum daily dietary exposure for a high-level consumer (if available) as the maximum food 
additive dose (Table 2). Of the OATP2B1 inhibitors identified, neohesperidin DC was the only additive where in 
vivo inhibition could be ruled out based on these calculations. For all other food additives, the resulting intestinal 
threshold concentrations for in vivo inhibition (0.1-fold the maximum dose/250 ml) are higher than the defined Ki 
values. For example, the concentrations calculated for Allura Red AC are 113-fold and 45-fold higher than the Ki 





Table 2. Estimated dietary exposure and estimation of intestinal concentrations [I] of selected food additives.  
Food additive 
Dietary exposurea 






Allura Red AC 
Ki (pH 7.4) = 0.6 µM 
Ki (pH 5.5) = 1.5 µM 
 
0.1–0.4 0.4–1.2 68 
Brilliant Black BN 
Ki (pH 5.5) = 3.8 µM 
 
0.05–0.30 0.23–0.69 22 
Brilliant Blue FCF 
Ki (pH 5.5) =17.7 µM 
 
0.6 3.0 106 
Carmoisine 
Ki (pH 7.4) = 7.0 µM 
Ki (pH 5.5) =2.7 µM 
 
0.04–0.3 0.2–0.9 50 
Curcumin 
Ki (pH 7.4) = 5.0 µM 
Ki (pH 5.5) = 5.3 µM 
 
0.2–0.6 0.4–1.5 114 
Neohesperidin DC 
Ki (pH 7.4) =35.4 µM 
Ki (pH 5.5) = 14.9 µM 
 
0.02d - 1 
Sunset Yellow FCF 
Ki (pH 5.5) = 19.6 µM 
0.01–0.1 0.1–0.4 25 
a Data from EFSA (European Food Safety Authority) exposure assessments (References 38–44). Data for maximum reported use level or 
brand-loyal scenario in adults, if not otherwise stated 
b 95th or 97th percentile 
c [I] Estimated intestinal concentration calculated according to EMA guidance (0.1-fold the maximum dose on one occasion/250 ml).37 The 
daily dietary exposure (maximum for high-level consumer, if available) for a 70 kg person was used as the maximum dose  
d Calculated from modified theoretical added maximum daily intake  
 
Based on the relationships between Ki values and intestinal exposure to food additives, in vivo studies would be 
justified to elucidate the impact of OATP2B1 inhibition by selected food additives.37 Considering that OATP2B1 
is the main OATP isoform in the intestine and it transports a broad range of drugs, in vivo inhibition of OATP2B1 
would be expected to alter the intestinal absorption of OATP2B1 substrate drugs given that OATP2B1 is a major 
contributor to absorption of the substrate. It would not be unforeseen if food additives would cause clinical drug 
interactions via OATP2B1 inhibition, as dietary and natural products, especially fruit juices, have shown to 
decrease the exposure of OATP2B1 substrate drugs.13 On the other hand, the lack of clinical OATP2B1-mediated 
drug–drug interactions can be considered rather surprising, as in vitro OATP2B1 inhibitors are not particularly 
rare among clinically used drugs.28 The reason could be that OATP2B1 is not the predominant mechanism in drug 
absorption in vivo as other contributing pathways may exist. Other reasons could be that OATP2B1 has been 
understudied and more clinical interactions appear when systematic research becomes common. As we 
demonstrated here, more OATP2B1 inhibitors were identified at acidic assay conditions, suggesting that potential 
intestinal OATP2B1 inhibitors could be overlooked if studied only at neutral pH 7.4. 
 
As we have previously demonstrated, food additives can inhibit other intestinal transporters as well.5 All food 
additives identified as OATP2B1 inhibitors in this study have been previously identified also as BCRP and/or 
MRP2 inhibitors.5,6 Considering that the consequences of intestinal apical efflux transporter inhibition are opposite 
to the effects of OATP2B1 uptake inhibition, the concurrent inhibition of both transporters could overrule the 
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estimated clinical effects for individual transporters taken that the substrate is also transported by both transporters. 
For example, curcumin can inhibit many intestinal drug transporters relevant for drug absorption (OATP2B1, 
BCRP, MRP2 and P-gp) as well as drug metabolizing enzymes in vitro,5,45 making extrapolation of in vivo effects 
complicated based on separate in vitro assays. However, inhibition of efflux transporters and drug metabolizing 
enzymes require inhibitor access to the transporter from intracellular side, which may not be achievable for food 
additives with limited absorption. Food additives can also be extensively metabolized during GI transit. For 
example, azo dyes are susceptible to bacterial azo reduction,46 and sweeteners neohesperidin DC, stevioside and 
rebaudioside A to bacterial deglycosylation.47,48 Notably, Zou et al.31 demonstrated that the reduced metabolites 
of azo dyes did not inhibit OATP2B1 in vitro, and that high (25 mg/kg) but not low (2.5 mg/kg) dose Allura Red 
AC decreased the exposure of fexofenadine in P-gp-deficient (mdr1a/b−/−) mice. These results suggest that high 
doses of azo dyes have the potential to saturate the azoreductase capacity of the gut microbiome, which then can 
result in intact dye concentrations high enough to cause observable intestinal OATP2B1 inhibition.31  
 
In conclusion, this study demonstrates that in addition to previously recognized inhibitory effects on ABC-efflux 
transporters,5,6 commonly used food additives can inhibit the intestinal uptake transporter OATP2B1 in vitro. Out 
of the 25 tested food additives, six colorants and one sweetener were validated as OATP2B1 inhibitors. Several 
colorants were found to inhibit OATP2B1 with inhibitory constants well below estimated intestinal food additive 
concentrations. We also demonstrated substrate- and pH-dependent inhibition of OATP2B1, as more inhibitors 
were identified when estrone sulfate was used as OATP2B1 substrate at pH 5.5 mimicking the acidic intestinal 
environment. Altogether, the results of this study suggest that high exposure to food additives could cause 
interindividual variability on the absorption of orally administered drugs, but considering the complexity of 
OATP2B1 modulation, further studies evaluating the overall in vivo effect of food additive–drug interactions are 
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Figure S1. Time-dependent uptake of (A) 1 µM dibromofluorescein (DBF) and (B) 0.5 µM estrone sulfate into 
HEK293 cells expressing OATP2B1 (○) or control (□). OATP2B1-mediated transport (●) was obtained by 
subtracting control uptake from OATP2B1 uptake. Uptake of DBF and estrone sulfate were studied at pH 7.4 and 







Table S1. Data used to analyze concentration-dependent uptake of DBF into OATP2B1 and control (eYFP) 
expressing HEK293 cells. OATP2B1-mediated uptake was obtained by subtracting control uptake from OATP2B1 






mg total protein/min) 
Control (eYFP) uptake 
(fluorescence unit/ 
mg total protein/min) 
OATP2B1-mediated uptake  
(fluorescence unit/ 
 mg total protein/min) 
0.01 1.72 ± 0.91 1.15 ± 0.68  0.56 ± 1.13  
0.1 13.89 ± 0.31 1.60 ± 0.93 12.29 ± 0.98 
0.5 54.13 ± 6.53 1.43 ± 0.24 52.70 ± 6.53 
2.5 171.65 ± 23.15 5.30 ± 0.84 166.36 ± 23.17 
5 202.29 ± 18.00 7.37 ± 0.75 194.92 ± 18.01 
15 303.79 ± 16.36 25.17 ± 0.44 278.61 ± 16.37 




Table S2. Data used to analyze concentration-dependent uptake of estrone sulfate into OATP2B1 and control 
(eYFP) expressing HEK293 cells. OATP2B1-mediated uptake was obtained by subtracting control uptake from 





(pmol/mg total protein/min) 
Control (eYFP) uptake 
(pmol/mg total protein/min) 
OATP2B1-mediated uptake  
(pmol/mg total protein/min) 
0.1 0.63 ± 0.09  0.10 ± 0.02 0.53 ± 0.09  
0.5 9.52 ± 0.18 0.65 ± 0.23 8.88 ± 0.18 
1 23.66 ± 4.61 1.12 ± 0.06 22.54 ± 4.61 
5 127.10 ± 18.58 4.77 ± 0.54 122.33 ± 18.58 
15 310.56 ± 83.48 8.71 ± 1.53 301.85 ± 83.48 
30 388.16 ± 54.89 17.37 ± 4.78 370.78 ± 54.89 
50 486.40 ± 69.01 40.15 ± 18.11 446.24 ± 69.01 








* p<0.05, compared to control 
 
Figure S2. Interference of food additives with dibromofluorescein (DBF) fluorescence assuming that food 
additives are completely retained in the final fluorescence sample. DBF (0.1 µM) fluorescence was measured with 
50 µM food additive in 0.1 M NaOH. Results are expressed as mean ± SD of three replicate measurements 







Figure S3. Solubility of food additives (50 µM) in transport buffer pH 7.4 or pH 5.5 measured with nephelometry. 
Results are expressed as mean ± SD (three replicates) relative nephelometric unit (RNU) of food additives in 












Table S3. Molecular properties of the tested food additives. The properties were calculated with ACD/Labs version 8.0 (Advanced Chemistry 
Development, Inc., Toronto, ON, Canada) for the parent compound. 
Food additive Catalog 
number 
E number MW 
(g/mol) 
PSA LogD7.4 LogD5.5 
Acesulfame K (potassium salt) 47134 E 950 163 81 -2.32 -2.32 
Advantame (monohydrate) 80054 E 969 459 134 -0.25 -0.03 
Allura Red AC (sodium salt) 38213 E 129 452 180 -1.64 -1.64 
Aspartame 47135 E 951 294 119 -1.49 -1.34 
Benzoic acid 33047 E 210 122 37 -0.98 0.58 
Betanin (red beet extract diluted with dextrin) CDS000584 E 162 551 247 -6.59 -6.42 
Brilliant Black BN (sodium salt) 11220 E 151 780 350 -7.64 -7.64 
Brilliant Blue FCF (sodium salt) 80717 E 133 750 195 -0.18 -0.17 
Carmoisine (sodium salt) 52245 E 122 458 170 -3.1 -3.07 
Curcumin C1386 E 100 368 93 2.84 2.92 
DL-Malic acid 240176 E 296 134 95 -5.99 -3.9 
Ethylparaben 111988 E 214 166 47 2.34 2.39 
Fumaric acid 47910 E 297 116 75 -4.75 -3.09 
Green S (sodium salt) 06737 E 142 556 152 0.98 1.25 
Methylparaben H5501 E 218 152 47 1.81 1.86 
Neohesperidin dihydrochalcone 75041 E 959 613 245 2.59 3.08 
Neotame 49777 E 961 378 105 1.07 1.17 
Rebaudioside A 01432 E 960 967 374 -1.12 -1.12 
Saccharin 109185 E 954 183 72 -1.09 -1.08 
Sodium cyclamate (sodium salt) 47827 E 952 179 75 -2.52 -2.4 
Sorbic acid S1626 E 200 112 37 -1.41 0.39 
Stevioside (hydrate) S3572 E960 805 295 1.19 1.19 
Sucralose PHR1342 E 955 398 129 0.68 0.68 
Sunset Yellow FCF (sodium salt) 465224 E 110 408 170 -3.3 -3.3 
Tartrazine (sodium salt) 03322 E 102 468 220 -6.63 -6.63 





Table S4. Inhibition of OATP2B1-mediated uptake of dibromofluorescein (DBF; 1 µM) at pH 7.4, and estrone sulfate (ES; 0.5 µM) at pH 5.5 by 
food additives at 50 µM concentration. Results are expressed as mean ± SD of OATP2B1-mediated uptake relative to control with DBF or estrone 
sulfate alone from one experiment with three replicates. For comparison, results from the study by Zou et al.1 are presented. 
Food additive DBF uptake 
(pH 7.4) 
(% of control) 
ES uptake  
(pH 5.5) 
(% of control) 
Zou et al.1 
DBF uptakeb 
(% of control) 
Ki  
(DBF pH 7.4) 
(µM) 
Ki  
(ES pH 5.5) 
(µM) 
Zou et al.1 Ki 
(µM) 
Acesulfame K 91.7 ± 2.8 94.2 ± 9.8 101 (10 µM) a a a 
Advantame 91.5 ± 6.5 91.3 ± 9.9 a a a a 
Allura Red AC 5.3 ± 1.0 4.4 ± 1.1 3.5 (200 µM) 0.6 1.5 2.59 
Aspartame 92.5 ± 7.1 92.0 ± 10.8 103 (200 µM) a a a 
Benzoic acid 71.9 ± 4.0 86.0 ± 3.4 a a a a 
Betanin 129.7 ± 32.9 97.3 ± 8.0 a a a a 
Brilliant Black BN 115.5 ± 13.2 3.6 ± 2.0 a a 3.8 a 
Brilliant Blue FCF 84.7 ± 6.0 13.1 ± 9.6 19.5 (200 µM) a 17.7 13.0 
Carmoisine 33.0 ± 6.9 5.5 ± 1.9 a 7.0 2.7 a 
Curcumin 7.0 ± 0.8 7.4 ± 1.9 a 5.0 5.3 a 
DL - Malic acid 80.3 ± 12.9 101.0 ± 11.4 D-(+) = 96.6 (200 µM) 
L-(−) = 92.5 (200 µM) 
a a a 
Ethyl paraben 147.7 ± 22.7 88.6 ± 4.1 74.6 (200 µM) a a a 
Fumaric acid 141.4 ± 9.7 93.1 ± 4.9 88.9 (200 µM) a a a 
Green S 128.9 ± 19.2 83.6 ± 8.4 a a a a 
Methyl paraben 126.3 ± 8.7 91.9 ± 14.8 92.2 (200 µM) a a a 
Neohesperidin DC 37.0 ± 5.4 20.9 ± 0.6 14.7 (200 µM) 35.4 14.9 20.1 
Neotame 74.2 ± 9.8 91.3 ± 13.8 67.1 (200 µM) a a a 
Rebaudioside A 43.5 ± 2.2 91.5 ± 7.3 a a a a 
Saccharin 69.9 ± 11.8 82.9 ± 2.7 97.1 (200 µM) a a a 
Sodium cyclamate 78.1 ± 15.3 98.0 ± 7.3 a a a a 
Sorbic acid 77.1 ± 3.1 92.8 ± 7.5 a a a a 
Stevioside 73.8 ± 5.8 109.1 ± 3.6 a a a a 
Sucralose 153.5 ± 8.9 90.2 ± 3.5 102 (1000 µM) a a a 
Sunset Yellow FCF 71.3 ± 6.3 28.5 ± 10.6 45.5 (50 µM) a 19.6 68.4 
Tartrazine 84.9 ± 17.5 80.0 ± 4.6 97.8 (200 µM) a a a 
a Not determined 






(1) Zou, L.; Spanogiannopoulos, P.; Pieper, L. M.; Chien, H.-C.; Cai, W.; Khuri, N.; Pottel, J.; Vora, B.; Ni, Z.; Tsakalozou, E.; Zhang, W.; 
Shoichet, B. K.; Giacomini, K. M.; Turnbaugh, P. J. Bacterial Metabolism Rescues the Inhibition of Intestinal Drug Absorption by Food 
and Drug Additives. Proc. Natl. Acad. Sci. U. S. A. 2020, 117 (27), 16009–16018. 
 
 
